Notice of Termination of RFA-TR-23-016 Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Notice Number:
NOT-TR-24-022
Key Dates
Release Date:
March 25, 2024
Related Announcements
- July 5, 2023 - Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed). See NOFO RFA-TR-23-016.
Issued by
National Center for Advancing Translational Sciences (NCATS)
Purpose
Effective immediately, the Notice of Funding Opportunity RFA-TR-23-016 "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) is terminated. Applications submitted to RFA-TR-23-016 will not be reviewed. NIH plans to re-issue (or has re-issued) this Notice of Funding Opportunity as “Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)” this spring.
Inquiries
Please direct all inquiries to:
Steven T. Pittenger, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-5810
Email:Steven.Pittenger@nih.gov
Department of Health
and Human Services (HHS)
and Human Services (HHS)
